SAN DIEGO, Nov. 29 /PRNewswire-FirstCall/ -- Three seasoned genetic analysis industry professionals joined Sequenom, Inc. to support the Company’s service business initiatives, it was announced today. Dr. Jeffrey Otto joins Sequenom as Director of Genetic Services, Dr. Min Seob Lee as Manager of Genetic Services and Mr. Donald Benson as National Account Manager - Genetic Services. Sequenom launched its new genetics analysis service business in October 2005.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)
Dr. Otto has over 10 years of management, leadership and research expertise and has experience in building and leading teams in start up and rapid growth environments. Prior to joining Sequenom as Director of Genetic Services, Dr. Otto held numerous positions of increasing responsibility from 2000 to 2005 at Genaissance Pharmaceuticals, Inc., most recently as Director of Business Development. From 1995 to 2000, Dr. Otto served as Principal Investigator and completed his post doctoral fellowship in the department of orthopedic surgery molecular biology and genetics laboratory at Rush-Presbyterian Department of Orthopedic Surgery-St. Luke’s Medical Center where he was an assistant professor. He received a Master of Business Administration degree from Ellis College of the New York Institute of Technology, a Ph.D. from Marquette University and a Bachelor of Arts degree in Biology from Carthage College. Dr. Otto is CLIA (Clinical Laboratory Improvement Amendments) licensed and a former New York State Department of Health Clinical Laboratory Evaluation Program licensed laboratory director.
Dr. Lee has over 5 years experience in the life sciences industry with scientific expertise in molecular biology, genomics, genetics and biotechnology which he has utilized in a variety of service settings, specializing in designing and building genetic tests in molecular laboratories in both high throughput research and CLIA regulated settings. Lee conducted his post-doctoral fellowship at Harvard Medical School, Beth Israel Deaconess Medical Center, received a Ph.D. in Biological Science from the City of Hope National Medical Center and Beckman Research Institute. He received a Master of Science degree in Biology from California State University, Los Angeles and a Bachelor of Science degree in Biology from Kyung-Hee University in Seoul Korea.
Mr. Benson joins Sequenom as National Account Manager with over 20 years pharmaceutical and biotechnology sales experience, including companies such as Bios Corporation, Boehringer Mannheim Biochemicals, Eppendorf North America, Genaissance, Orchid Biosciences, QIAGEN and Protein-DNA Imageware. Benson holds a Bachelor of Science degree from Rutgers University.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, molecular medicine and agricultural applications. The Company’s proprietary MassARRAY(R) system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts.
Sequenom(R) and MassARRAY(R) are registered trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom’s technologies, the development and commercialization of any new service, including its new genetics analysis service business, technology, product or application, and Sequenom’s ability to execute its business strategy, and other risks detailed from time to time in Sequenom’s SEC filings, including Sequenom’s Annual Report on Form 10-K for the year ended December 31, 2004, and its most recently filed quarterly report on Form 10-Q. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSequenom, Inc.
CONTACT: Investor Relations, Amy Caterina of Sequenom, Inc.,+1-858-202-9033, acaterina@sequenom.com
